An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered With Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, With Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extension Phase
To describe the pharmacokinetic (PK) profile of sarilumab in patients aged 1-17 years with
Systemic Juvenile Idiopathic Arthritis (sJIA) in order to identify the dose and regimen for
adequate treatment of this population.
To describe the pharmacodynamics (PD) profile, the efficacy, and the long term safety of
sarilumab in patients with sJIA.
The total study duration per patient will be 166 weeks that will consist of a 4- week
screening, a 12-week core treatment phase, a 144-week extension phase, and a 6-week
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.